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Overexpression and/or activity of c-Src non-receptor tyrosine kinase is associated with progression of several human epithelial
cancers including breast cancer. c-Src activity in ‘pure’ ductal carcinoma in situ (DCIS) was measured to assess whether this predicts
recurrence and/or correlates with HER2 expression and other clinical parameters. Activated c-Src levels were evaluated in DCIS
biopsies from 129 women, with median follow-up at 60 months. High levels of activated c-Src correlated with HER2 positivity, high
tumour grade, comedo necrosis and elevated epithelial proliferation. In univariate analysis, high activated c-Src level associated with
lower recurrence-free survival at 5 years (P¼0.011). Thus, high c-Src activity may identify a subset of DCIS with high risk of
recurrence or progression to invasive cancer where therapeutics targeting c-Src may benefit this patient subset.
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Overexpression and/or increased activity of c-Src non-receptor
tyrosine kinase is associated with development of many human
carcinomas including breast cancer (Irby and Yeatman, 2000)
where it is elevated early in disease progression (Verbeek et al,
1996). c-Src overexpression is also associated with breast tumour
metastasis (Guy et al, 1994; Muthuswamy and Muller, 1994),
especially to bone (Myoui et al, 2003). The molecular events
driving c-Src activation in breast cancers are unclear although
this can occur downstream of activated receptor tyrosine kinases
(RTKs) including HER2/erbB2 (Muthuswamy et al, 1994; Belsches-
Jablonski et al, 2001). Overexpression of constitutively activated
Src drives oncogenic processes that could contribute to latter
stages of carcinogenesis and most prominently, increased motility
and invasion (Frame, 2004). Few studies have examined subtypes
of breast cancer with respect to c-Src activity and as Src-targeted
therapies are entering the clinic, data are now required to
determine which patient groups (disease type and stage) might
optimally benefit.
There is a 12–20% recurrence rate at 10 years following breast
conserving surgery and adjuvant radiotherapy for DCIS and up to
half of recurrences are invasive carcinomas (Fisher et al, 1999).
c-Src binds to, and can be activated by HER2 and appears to play
a critical role in HER2-mediated breast cancer invasion and
metastasis (Tan et al, 2005). Here, we investigated whether high
levels of active c-Src are associated with clinico-pathological
factors including HER2 status and early recurrence of DCIS.
MATERIALS AND METHODS
Patients and tissues
One hundred and twenty-nine cases of women diagnosed with
‘pure’ DCIS (median patient age 55 years, median follow-up 60
months) were selected from the University Hospital of South
Manchester database. Thirty-five cases recurred within 5 years and
94 cases had not recurred. All specimens were formalin-fixed and
paraffin-embedded. Patient age, histological nuclear grade, tumour
size, follow-up and recurrence times were retrieved from our unit
database (Barnes et al, 2005). Ethical approval was from South
Manchester University Hospital Ethics Board.
Immunohistochemistry and Western blotting
mAb Clone 28 recognizes an epitope adjacent to Tyrosine 530 in
the C terminal regulatory domain of activated c-Src (Kawakatsu
et al, 1996). Sections (4mm) of tissue were processed as previously
described (Boland et al, 2004) before incubation with Clone 28
(1:800) for 60min. Antibody binding was detected using anti-
mouse DakoCytomation EnvisionþSystem HRP kit (Dako, UK).
Incubation time with 3.30-diaminobenzidine and substrate-
chromogen depended on positive control staining intensity
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s(B8min). Sections were counterstained as previously described
(Boland et al, 2004). Mouse IgG2ak (1:50) provided a negative
control. HCT116 cells engineered to inducibly express wild-type
(wt) or constitutively activated c-Src (c-SrcY527F) (Welman
et al, 2005) were used as positive control pellets, processed and
analysed identically to clinical specimens. Induction of wt c-Src (or
c-SrcY527F) was confirmed by Western blotting using pAb rabbit
anti-Src (pY418, Biosource, UK no. 44-660). Activated c-Src
staining was also investigated in a MDA MB231 breast cancer cell
tumour xenograft, chosen as this cell line exhibits high levels of
activated c-Src measured by Western blotting (Ito et al, 2002).
Activated c-Src expression was also evaluated in sections of normal
breast ductal epithelium by IHC. Inter-assay variation was assessed
in high and low scoring sections form one batch in the subsequent
batches. All slides were examined and scored by two independent
observers, one blinded to clinical outcome. Total cellular activated
c-Src staining intensity was scored using a scale of 0 (negative),
1 (low), 2 (moderate) and 3 (high). To qualify as 3, 2 and 1 dark
staining of 100, 470 or o70% of tumour cells had to be observed.
The IHC evaluation of ER status, HER2 expression and Ki67 levels
was as previously described (Boland et al, 2004). To assess intra-
and inter-observer variability, 60 sections were selected at random
and scored twice by the same observer (G.W., 4 of 60 scores
differed) and scored independently by two observers (G.W.
and A.C, 3 of 60 cases scores differed). Slides that differed were
re-analysed in conference and a representative score agreed.
RESULTS
Activated c-Src staining in different breast tissue
Initially, the ability of clone 28 to recognize activated c-Src using
the IHC protocols above was confirmed using HCT116 cell pellet
controls. When high levels of wt c-Src (Figure 1A(iii), (or c-Src
Y527F, not shown), were induced, staining was strongly positive
compared to uninduced cells (Figure 1Aii). Controls with mouse
IgG did not stain (Figure 1A(i)). Western blotting confirmed that
wt c-Src was activated in HCT116 when induced (Figure 1 inset)
thus these data together confirmed that clone 28 can reliably probe
active c-Src by IHC. Figure 1A(v) shows positive staining with
clone 28 staining of the MDA MB231 breast cancer cell xenograft
consistent with the reported high levels of this breast cell line
(Ito et al, 2002).
Activated c-Src staining was detected in all DCIS specimens with
higher levels in DCIS compared with normal breast tissue, and
correlated positively with tumour nuclear grade (Figure 1B(i–iv)).
Low-level-activated c-Src was detected in 12% normal breast tissue
sections. Of 129 DCIS tumours analysed 19% tumours expressed
low activated c-Src levels, 41% expressed moderate and 40%
expressed high levels. Moderate immuno-reactivity was often
observed in lymphocytes surrounding DCIS.
Activated c-Src expression vs clinico-pathological variables
Table 1 summarises the relationship between expression of total
cellular activated c-Src and clinico-pathological factors. High levels
of activated c-Src in DCIS was associated with HER2 positivity
(Po0.0005), high tumour nuclear grade (Po0.0005), the presence
of comedo necrosis (P¼0.001) and high Ki67 scores (P¼0.025),
but not with ER status (P¼0.973), tumour size (P¼0.403) and
EGFR/HER1 expression (P¼0.507).
Activated c-Src and recurrence-free survival
Univariate analysis Activated c-Src level was a significant
predictor of DCIS recurrence at 5 years (P¼0.011). Patients with
DCIS expressing higher levels of activated c-Src had a poorer
cumulative 5 year disease-free survival compared to those with low
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Figure 1 (Ai–v) Experimental controls for Clone 28 immunohisto-
chemistry of activated c-Src. Pellets of untreated or doxycycline treated
HCT116 colon cancer cells that express a doxycycline-inducible, wild-type
(wt) c-Src. High levels of activated c-Src were detected in doxycyline
treated HCT116 colon cancer cells harbouring the doxycycline-inducible
wt c-Src (Aiii). Detectable but lower levels of active c-Src were detected
in these HCT116 cells in the absence of doxycyline treatment (Aii).
Induction of wt c-Src was independently confirmed by western blotting
using an anti Src[pY
418] antibody specific for autophosphorylated active c-
Src (Figure 1A insert. No significant immunoreactivity was detected in
HCT116 cells analysed by mouse IgG2a, which served as a negative control
(Ai). Figure 1A(iv) shows a section of a MDA MB231 tumour xenograft
negative control (IgG2A) and 1A(v) shows clone positive staining
with Clone 28 in this xenograft indicative of high levels of activated c-Src.
(Bi–iv) Immunohistochemistry for activated c-Src using clone 28 in normal
breast epithelium (Bi), and DCIS tumours (Bii–iv). Low levels of activated
c-Src in B(ii), moderate levels in B(iii) and high levels in B(iv). A higher
level of activated c-Src was detected in DCIS tumours compared with
normal breast. There was a positive correlation between the level of
activated c-Src and tumour nuclear grade (Po0.0005). The scale bar equals
50mm.
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slevels (61.7 vs 92%, P¼0.011, Figure 2). Of the 35 DCIS tumours
that recurred by 5 years, 6% expressed low levels of activated c-Src,
43% expressed moderate levels and 51% expressed high levels
(Figure 2). Other factors including HER2 status, Ki67, tumour
nuclear grade, margin status and patient age were also significant
predictors of disease recurrence (Table 2).
Multivariate analysis Higher tumour nuclear grade, involved
margins (o1mm) and higher patient age (X50 years) were
independently associated with an increased risk of recurrence
at 5 years (Table 3). Activated c-Src level was not a significant
independent predictor of recurrence-free survival.
Activated c-Src vs recurrence pathology
Of the 35 women with recurrent DCIS, 37% had invasive
recurrences and 63% had DCIS recurrence. The median recurrence
time for invasive carcinoma was 24 months, compared with 13
months for DCIS recurrences. There was no significant difference
between the level of activated c-Src and onset of DCIS recurrences
Table 1 Correlations between the total cellular expression levels of
activated c-Src (low, moderate, and high) and clinicopathologic factors in
129 DCIS tumours
Level of activated c-Src
Clinical Factor Low (n¼25)
Moderate
(n¼53) High (n¼51) P-value
HER1 status (n¼43)
Positive (X2) 5 10 15
Negative (o2) 3 6 4 0.507
a
HER2 status (n¼125)
Positive (X2) 10 29 42
Negative (o2) 15 21 8 o0.0005
a
ER status (n¼126)
Positive 16 34 32
Negative 8 18 18 0.973
a
Ki67 (n¼125)
Median 11.2 11.0 13.7
Range 2.5–31.4 1.3–61.1 2.6–46.0 0.025
b
Tumour nuclear grade (n¼128)
Low 5 4 0
Intermediate 11 21 6
High 9 27 45 o0.0005
a
Histological type (n¼125)
Comedo 3 11 11
Mixed comedo 6 22 32
Non-comedo 14 20 6 0.001
a
Tumour size (mm) (n¼123)
Median 17.5 13.5 20
Range 5–40 4–43 4–75 0.403
b
High expression levels of activated c-Src in DCIS correlated with HER2 positivity, high
tumour grade, the presence of comedo necrosis and higher epithelial proliferative
status but not with tumour size, ER status and EGFR expression. Statistical analysis:
aw
2 test.
bKruskall–Wallis test.
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Figure 2 In univariate analysis, Kaplain–Meier plot of cumulative local
recurrence (DCIS and invasive breast carcinoma) for 129 patients with
DCIS. Low-activated c-Src expressing DCIS tumours had a significant
disease-free survival advantage over DCIS expressing moderate to high
levels of activated c-Src.
Table 2 Univariate analysis of predictors of DCIS recurrence at 5 years
using the log rank test
Clinical factor
Non-recurrent
(n¼94)
Recurrent
(n¼35) P-value
HER2 status (%) (n¼125)
Positive (X2) 52 (57.8) 29 (82.9)
Negative (o2) 38 (42.2) 6 (17.1) 0.01
Ki67 score (%) (n¼125)
o12.2 (median) 52 (57.8) 10 (28.6)
X12.2 38 (42.2) 25 (71.4) 0.006
Activated c-Src (%) (n¼129)
Low 23 (24.5) 2 (5.7)
Moderate 38 (40.4) 15 (42.9)
High 33 (35.1) 18 (51.4) 0.011
ER status (%) (n¼126)
Positive 61 (67.0) 21 (60.0)
Negative 30 (33.0) 14 (40.0) 0.524
Tumour grade (%) (n¼128)
Low 9 (9.7) 0 (0.0)
Intermediate 34 (36.5) 4 (11.4)
High 50 (53.8) 31 (88.6) 0.0003
Margins (%) (n¼129)
Involved (o1mm) 78 (83.0) 19 (54.3)
Clear (X1mm) 16 (17.0) 16 (45.7) 0.001
Patient age (years) (n¼129) (%)
o50 6 (6.4) 8 (22.9)
X50 88 (93.6) 27 (77.1) 0.019
HER2 positivity, high epithelial proliferation, high levels of total cellular activated c-Src,
high tumour nuclear grade, involved margins and young age at presentation were
associated with a higher disease recurrence at 5 years.
Table 3 Independent predictors of DCIS recurrence in the patient
group (n¼129), carried out using Cox proportional hazards regression
analysis
Clinical factor B s.e. Exp (B) 95% CI for Exp (B) P-value
Margin status
Involved (o1mm) 0.967 0.344 2.63 1.34–5.17 0.005
Patient age
o50years 1.53 0.414 4.64 2.06–10.46 o0.0005
Tumour nuclear grade
High 1.751 0.536 5.76 2.01–16.47 0.001
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months). Of the 13 primary DCIS tumours that recurred as
invasive carcinomas, 46% were moderate and 54% were high
scores for activated c-Src. Of the 22 primary tumours that recurred
as DCIS, 9% scored low 41% scored moderate and 50% scored high
for activated c-Src.
DISCUSSION
Available data on activated c-Src levels in breast cancer relates
mainly to invasive breast carcinoma. Our data combined with that
of others (Ito et al, 2002; Diaz et al, 2006; Madan et al, 2006;
Planas-Silva et al, 2006), suggests that compared to normal
breast epithelium, increased levels of activated c-Src are present in
DCIS and invasive breast carcinoma. Activated c-Src levels
correlated with HER2 expression, a higher tumour nuclear grade,
the presence of comedo necrosis, and higher epithelial prolifera-
tive status. Furthermore, high expression of activated c-Src
correlated with significantly lower recurrence-free survival at 5
years. Consistent with the physical interactions between HER2
and c-Src, we observed a significant association between HER2
expression and activated c-Src. These data also resonate with
function testing studies where overexpression of HER2 in
transgenic mouse systems (Muthuswamy et al, 1994) and
mammary epithelial cells (Sheffield, 1998) that resulted in c-Src
activation. HER2 activation in human breast cancer cells increased
c-Src protein level by driving its synthesis and/or stabilisation
(Tan et al, 2005). However, highly expressed activated c-Src was
also seen in HER2 negative DCIS thus HER2 independent pathways
for activation must exist.
Although HER2 can activate c-Src, it is unclear if c-Src promotes
proliferation. Discrepancies exist between activated c-Src levels
and proliferation in invasive breast carcinoma (Ito et al, 2002).
Here, activated c-Src levels positively correlated with increased cell
proliferation but we cannot ascribe causality and there was no
significant correlation between activated c-Src and tumour size.
Although numerous studies have demonstrated elevated c-Src
activity in breast carcinoma (Jacobs and Rubsamen, 1983;
Ottenhoff-Kalff et al, 1992; Verbeek et al, 1996), there have been
discrepancies between tumour histological grade and activated c-
Src (Ito et al, 2002). Here, levels of activated c-Src in DCIS strongly
correlated with tumour nuclear grade (Figure 1B (ii–iv)) and
comedo necrosis.
Elevated c-Src activity leads to inhibition of matrix metallopro-
teinases (Noritake et al, 1999), disruption of cell–cell adhesions
(Yeatman, 2004) and enhances the migratory potential of tumour
cells (Frame, 2002). We report here, that moderate to high levels of
activated c-Src in DCIS recurred as invasive breast carcinomas and
that increased activated c-Src level was a significant, but not
independent predictor of disease recurrence.
In conclusion, we detected elevated activated c-Src in HER2
positive, high nuclear grade, DCIS tumours with a higher
proliferative index and comedo necrosis. Our data support the
hypothesis that in DCIS, c-Src may play a role in tumour
proliferation, development of higher grade lesions and may
facilitate progression to invasive recurrences and as such represent
tractable drug targets in both DCIS and invasive breast carcino-
mas. HER2 overexpression in invasive breast cancer is associated
with an aggressive phenotype, resistance to hormonal therapy
and poor survival (e.g. Slamon et al, 1987). Only a third of HER2-
overpressing metastatic breast cancers respond to Trastuzumab
(Herceptin), a function blocking anti-HER2 antibody (Vogel et al,
2002). c-Src targeted drugs are entering early clinical trials, and it
is possible in appropriate patient cohorts that c-Src targeted drugs
will be of benefit and that combination therapy with a c-Src
inhibitor plus Herceptin may be superior to Herceptin alone.
ACKNOWLEDGEMENTS
We thank Miss Nicola Barnes, the Department of Academic
Surgery, and the surgical staff from the South Manchester
University and The Christie Hospital NHS Trust, Manchester,
UK. We also thank Mr M Seenath, Dr Catharine West and
Mr Garry Ashton for their assistance with the immunohistochem-
ical staining and analysis of activated c-Src. We dedicate this paper
to Dr H Kawakatsu (Lung Biology Centre, University of California,
San Fransisco, USA & Co-founder A-Cube Inc.) who died during
this study.
Additional Support
GW, British Journal of Surgery Bursary Award.
RBC & CD, Cancer Research-UK
REFERENCES
Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ
(2005) Absence of HER4 expression predicts recurrence of ductal
carcinoma in situ of the breast. Clin Cancer Res 11: 2163–2168
Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA,
Parsons SJ (2001) Src family kinases and HER2 interactions in human
breast cancer cell growth and survival. Oncogene 20: 1465–1475
Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2
expression is associated with an aggressive phenotype in ductal
carcinoma in situ. Br J Cancer 90: 423–429
Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I,
Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D,
Jove R, Muro-Cacho CA (2006) Activation of stat3 in primary
tumors from high-risk breast cancer patients is associated with elevated
levels of activated SRC and survivin expression. Clin Cancer Res 12:
20–28
Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark
N (1999) Pathologic findings from the National Surgical Adjuvant Breast
Project (NSABP) eight-year update of Protocol B-17: intraductal
carcinoma. Cancer 86: 429–438
Frame MC (2002) Src in cancer: deregulation and consequences for cell
behaviour. Biochim Biophys Acta 1602: 114–130
Frame MC (2004) Newest findings on the oldest oncogene; how activated
src does it. J Cell Sci 117: 989–998
Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ (1994)
Activation of the c-Src tyrosine kinase is required for the induction of
mammary tumors in transgenic mice. Genes Dev 8: 23–32
Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human
cancer. Oncogene 19: 5636–5642
Ito Y, Kawakatsu H, Takeda T, Tani N, Kawaguchi N, Noguchi S, Sakai T,
Matsuura N (2002) Activation of c-Src is inversely correlated with
biological aggressiveness of breast carcinoma. Breast Cancer Res Treat
76: 261–267
Jacobs C, Rubsamen H (1983) Expression of pp60c-src protein kinase in
adult and fetal human tissue: high activities in some sarcomas and
mammary carcinomas. Cancer Res 43: 1696–1702
Kawakatsu H, Sakai T, Takagaki Y, Shinoda Y, Saito M, Owada MK, Yano J
(1996) A new monoclonal antibody which selectively recognizes the
active form of Src tyrosine kinase. J Biol Chem 271: 5680–5685
Madan R, Smolkin MB, Cocker R, Fayyad R, Oktay MH (2006) Focal
adhesion proteins as markers of malignant transformation and
prognostic indicators in breast carcinoma. Hum Pathol 37: 9–15
Muthuswamy SK, Muller WJ (1994) Activation of the Src family of tyrosine
kinases in mammary tumorigenesis. Adv Cancer Res 64: 111–123
Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ (1994)
Mammary tumors expressing the neu proto-oncogene possess elevated
c-Src tyrosine kinase activity. Mol Cell Biol 14: 735–743
Activated c-Src in DCIS
GR Wilson et al
1413
British Journal of Cancer (2006) 95(10), 1410–1414 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sMyoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T,
Mundy GR, Yoneda T (2003) C-SRC tyrosine kinase activity is associated
with tumor colonization in bone and lung in an animal model of human
breast cancer metastasis. Cancer Res 63: 5028–5033
Noritake H, Miyamori H, Goto C, Seiki M, Sato H (1999) Overexpression
of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in meta-
static MDCK cells transformed by v-src. Clin Exp Metastasis 17: 105–110
Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA,
Staal GE (1992) Characterization of protein tyrosine kinases from human
breast cancer: involvement of the c-src oncogene product. Cancer Res 52:
4773–4778
Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J (2006) Role
of c-Src and focal adhesion kinase in progression and metastasis of
estrogen receptor-positive breast cancer. Biochem Biophys Res Commun
341: 73–81
Sheffield LG (1998) C-Src activation by ErbB2 leads to attachment-
independent growth of human breast epithelial cells. Biochem Biophys
Res Commun 250: 27–31
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL
(1987) Human breast cancer: correlation of relapse and survival
with amplification of the HER-2/neu oncogene. Science 235:
177–182
Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D (2005)
ErbB2 promotes Src synthesis and stability: novel mechanisms of
Src activation that confer breast cancer metastasis. Cancer Res 65: 1858–
1867
Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE,
Geertzema JG, Hennipman A, Rijksen G (1996) c-Src protein expression
is increased in human breast cancer. An immunohistochemical and
biochemical analysis. J Pathol 180: 383–388
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L,
Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ,
Press M (2002) Efficacy and safety of trastuzumab as a single agent
in first-line treatment of HER2-overexpressing metastatic breast cancer.
J Clin Oncol 20: 719–726
Welman A, Cawthorne C, Barraclough J, Smith N, Griffiths GJ, Cowen RL,
Williams JC, Stratford IJ, Dive C (2005) Construction and characteriza-
tion of multiple human colon cancer cell lines for inducibly regulated
gene expression. J Cell Biochem 94: 1148–1162
Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470–480
Activated c-Src in DCIS
GR Wilson et al
1414
British Journal of Cancer (2006) 95(10), 1410–1414 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s